Verastem Inc
2VSA
Company Profile
Business description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Contact
117 Kendrick Street
Suite 500
NeedhamMA02494
USAT: +1 781 292-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
73
Stocks News & Analysis
stocks
Investors overly negative on undervalued ASX share
Road to profitability is in sight as management continues to take the right steps.
stocks
Reporting season preview: February 2025
As of Wednesday, 24 companies under coverage have reported; you’ll find our analysis throughout this issue.
stocks
Signs of a turnaround for undervalued ASX share
Market likes the payoff from early efforts at reining in costs.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,811.90 | 13.20 | -0.15% |
CAC 40 | 8,184.41 | 5.87 | 0.07% |
DAX 40 | 22,705.62 | 192.20 | 0.85% |
Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
FTSE 100 | 8,752.61 | 20.15 | 0.23% |
HKSE | 22,616.23 | 4.10 | -0.02% |
NASDAQ | 20,026.77 | 81.13 | 0.41% |
Nikkei 225 | 39,174.25 | 24.82 | 0.06% |
NZX 50 Index | 13,068.93 | 79.75 | 0.61% |
S&P 500 | 6,114.63 | 0.44 | -0.01% |
S&P/ASX 200 | 8,537.10 | 18.70 | -0.22% |
SSE Composite Index | 3,355.83 | 9.11 | 0.27% |